Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Patrick Balthrop, Erik Holmlin, Gene Cartwright, Lynn L'Archeveque


Luminex President and CEO Patrick Balthrop has been elected to the Personalized Medicine Coalition's board of directors for a three-year term.

The PMC represents industry, academic, and patient advocacy interests and seeks to advance personalized medicine and to educate policy-makers and the public. Balthrop has headed Luminex since 2004, and he previously was president of Fisher HealthCare.

Nanosphere has added two new members, Erik Holmlin and Gene Cartwright, to its board of directors, increasing the number of directors from five to seven.

Holmlin is president and CEO of BioNano Genomics, and he formerly held the same posts at GenVault. He also was chief commercial officer at Exiqon, led the formation of GeneOhm Sciences, and was vice president of marketing and development for Becton Dickinson Diagnostics after it acquired GeneOhm.

Cartwright was CEO of Omynx, a joint venture between GE and the University of Pittsburgh Medical Center, for four years, and before that he was president of Molecular Diagnostics for GE Healthcare, and division vice president and general manager of Molecular Diagnostics for Abbott Diagnostics.

Life BioScience has appointed Lynn L'Archeveque as director and sales and marketing.

In her new role, L'Archeveque will oversee the Albuquerque, NM-based Life Bioscience's line of microarray products and services for the research and clinical diagnostic fields, and will introduce its next-generation, three-dimensional slides to the market, the company said.

L'Archeveque has 15 years of experience in biotechnology including former positions with Exelixis, Biocompare, and Schott North America.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.